EUVIMEDEUVIMED entdecken
Crossref

Impact of Antifibrotic Adherence and Dosing on Risk of Mortality and Hospitalization in Idiopathic Pulmonary Fibrosis

Huiping Xu, Erin Meier, Mamta S Chhabria, Alison M DeDent, Siu L Hui, Zuoyi Zhang, Ryan D Boente

CHEST · 2026

DOI: 10.1016/j.chest.2026.03.040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CHEST, 2026. Verfasst von Huiping Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Indoles, Hospitalization, Pyridones. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Antifibrotics, including nintedanib and pirfenidone, are effective in slowing the decline of lung function for patients with idiopathic pulmonary fibrosis (IPF). However, their adoption rates are remarkably low, and substantial proportions of patients undergo dose reduction or treatment discontinuation because of the high incidence of adverse events. RESEARCH QUESTION: What is the impact of treatment modification on all-cause mortality and hospitalization? STUDY DESIGN AND METHODS: Using a large administrative database, patients with IPF were identified who initiated antifibrotic treatment. A nested case-control design was used to match cases and controls at a 1:1 ratio, and conditional logistic regression was performed to estimate the effect of antifibrotic adherence and dosing. Adherence was measured by using the proportion of days covered. Both adherence and dosing were determined based on the exposure period between antifibrotic initiation (cohort entry date) and outcome occurrence (index date). RESULTS: Adherence (proportion of days covered ≥ 0.75) was associated with lower risk of mortality (odds ratio, 0.563; P < .001), regardless of which antifibrotic was used. Patients taking a reduced dose had a significantly greater risk of mortality compared with those taking the standard dose (OR, 1.57; P = .024), but this was only observed in those who started nintedanib. For hospitalization, adherence was associated with a lower risk (OR, 0.692; P = .016) overall, and reduced doses were associated with a higher risk (OR, 1.667; P = .008) only among patients who started nintedanib. Among patients who started pirfenidone, neither adherence nor dose was associated with the risk of hospitalization. INTERPRETATION: The results of this study suggest that antifibrotic adherence and dosing are important factors that influence mortality and hospitalization. A multidisciplinary approach involving nutritionists, drug clinical educators, and other key stakeholders to facilitate early access, affordable treatment, and adverse event mitigation may enhance adherence and ultimately improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisIndolesHospitalizationPyridonesAntifibrotic AgentsDrug MonitoringHumansFemaleMaleAgedCase-Control StudiesMiddle AgedDose-Response Relationship, Drug

Stichwörter der Autor:innen

antifibroticshospitalizationidiopathic pulmonary fibrosismortalitynested case-control study

Substanzen

IndolesnintedanibPyridonespirfenidoneAntifibrotic Agents

Autor:innen und Institutionen

  • Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN.
  • Division of Pulmonary and Critical Care Medicine, NYU Langone Hospital, Long Island, Mineola, NY.
  • Department of Pulmonary and Critical Care, Mayo Clinic Health System, Eau Claire, WI.
  • Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University, Indianapolis, IN; Department of Medicine, School of Medicine, Indiana University, Indianapolis, IN; Indiana University Center fo…
  • AbbVie Inc, North Chicago, IL.
  • Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University, Indianapolis, IN. Electronic address: rboente@iu.edu.

Zitieren

APA

Xu, H., Meier, E., Chhabria, M. S., DeDent, A. M., Hui, S. L., Zhang, Z., & Boente, R. D. (2026). Impact of Antifibrotic Adherence and Dosing on Risk of Mortality and Hospitalization in Idiopathic Pulmonary Fibrosis. CHEST. https://doi.org/10.1016/j.chest.2026.03.040

Vancouver

Xu H, Meier E, Chhabria MS, DeDent AM, Hui SL, Zhang Z, et al. Impact of Antifibrotic Adherence and Dosing on Risk of Mortality and Hospitalization in Idiopathic Pulmonary Fibrosis. CHEST. 2026. doi:10.1016/j.chest.2026.03.040

BibTeX
@article{Xu2026,
  author = {Xu, Huiping and Meier, Erin and Chhabria, Mamta S and DeDent, Alison M and Hui, Siu L and Zhang, Zuoyi and Boente, Ryan D},
  title = {Impact of Antifibrotic Adherence and Dosing on Risk of Mortality and Hospitalization in Idiopathic Pulmonary Fibrosis},
  journal = {CHEST},
  year = {2026},
  doi = {10.1016/j.chest.2026.03.040}
}
Kostenlos starten →